Mirror Biologics is an international biopharmaceutical company headquartered in Tampa, Florida with operations in Jerusalem, Israel, Kuala Lumpur, Malaysia and Bangkok, Thailand. We are developing off-the-shelf, non-genetically manipulated, living immune cell therapies for metastatic solid tumors and as universal vaccine against respiratory viral infection in the elderly. In Tampa, we operate a 21 CFR 1271 registered blood donor center and conduct advanced bioreactor research and prototype development for commercial cell therapy manufacturing and also operate a clinical immunology lab for analysis of clinical samples. In Jerusalem we operate a GMP cell manufacturing and research facility. We also have clinical support and cold chain distribution operations in Bangkok, Thailand and Kuala Lumpur, Malaysia. The Mirror Effect technology platform enables reverse engineering of known effective immune responses and imprinting of these immune cascades upon failed immune systems. Mirror Effect technology is protected by over 200 patents issued worldwide. The lead drug, AlloStim, is a patented, disease-agnostic, allogeneic living immune cell differentiated from precursor cells purified from blood of healthy donors and formulated with monoclonal antibody-coated microparticles. The unique feature of AlloStim is that can imprint a protective or therapeutic cellular immune response that is customized to a patients resident disease without the need to have prior knowledge of the type of cancer/virus or genetic properties/antigenic structure of the disease. Proprietary artificial lymph node bioreactors are under development which are designed for high volume, high density scale-up of AlloStim. Novel frozen dosage forms enable extended shelf life and economical distribution. Mirror Biologics purchased the exclusive, worldwide rights to AlloStim and the Mirror Effect technology platform from Immunovative Therapies, Ltd, an Israeli company.